|
Variable
|
Total
|
|---|
|
Total patients
|
65
|
|
Median Age (range)
|
45 (11–73)
|
|
Male/female
|
48/17
|
|
Diagnosis
|
|
AML
|
47
|
|
MDS
|
5
|
|
Lymphoma
|
6
|
|
CML
|
2
|
|
Other leukemia
|
5
|
|
Disease status before second HCT
|
|
Remission
|
13
|
|
Not in remission
|
52
|
|
Donor status
|
|
MRD
|
33
|
|
MUD
|
21
|
|
Haplo-cord
|
11
|
|
Conditioning regimen for first HCT
|
|
Myeloablative
|
19
|
|
RIC
|
46
|
|
Conditioning regimen for second HCT
|
|
Myeloablative
|
44
|
|
Flu-Bu-Alemtuzumab
|
18
|
|
TBI-based
|
7
|
|
Bu/Cy
|
7
|
|
RIC
|
21
|
|
Flu-mel-Alemtuzumab
|
5
|
|
Clo-mel-Alemtuzumab
|
7
|
|
Flu-mel-ATG
|
7
|
- MRD matched related donor, MUD matched unrelated donor, MDS myelodysplastic syndrome
